CRVO

Cervomed Inc (CRVO) | Rumor.io

Cervomed

CRVO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,647

Bullish sentiment (50-day avg)53%

Price to earnings ratio4.86

Market capitalization40.4M

Earnings per share-3.21

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-27M

Social

What share of all stock conversation is about CRVO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Sep 29

The stock price of CervoMed Inc. (CRVO) has seen a 42% drop in a short period of time, prompting questions about trading psychology and whether to freeze, fight, or run.
A user suggests that CRVO could see traction with a 20/50 cross to the 3's, indicating a potential technical analysis opportunity.
The stock has seen a significant increase in volume, and some users are optimistic about the company's prospects, with one user stating that "the tipping point is here" and predicting higher prices.

Generated by AI

Sentiment

Of the messages about CRVO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% -50	50% -25	58.33% +7.39	85.63% +10.66
Bearish	50% new	50% +25	41.67% -7.39	14.37% -10.66

Bullish· Jul 8

Morgan Stanley's purchase of CRVO is a bullish sign, and investors who haven't bought yet may still have a chance to do so at a lower price.
The stock's +700% all-time gain has caught the attention of investors, with a target price of $1.40 identified.
CRVO's momentum and the AI boom's need for real-world infrastructure make it a strong investment opportunity, with a target price of $1.35.

Bearish· Jun 22

$CRVO is considered a giant shit fraud stock that will likely be in the red.
A reverse split is expected to occur in less than 3 months, potentially impacting the stock's value.
Investors who got burned by a previous offering may be wary of another potential collapse, citing similar Wall Street games.

Generated by AI

Topics

Of the messages about CRVO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	30.7%
Technical Analysis	—	0%	0%	5.31%
Analysts	—	0%	0%	33.18%
Controversies	—	0%	0%	0.4%
Earnings	—	0%	0%	0.12%
Macro	—	0%	0%	30.29%

Analysts· Mar 13

Chardan Capital upgraded CervoMed (CRVO) to Buy from Neutral with a $14 price target, citing compelling 16-week data from the open label extension phase of the company's Phase 2b study.
Jones Trading adjusted their stance on CervoMed (CRVO) to Buy with a target price of $15, and JonesResearch upgraded CervoMed to Buy from Hold with a $15 price target, arguing that the company's latest data is boosting investor confidence.
Chardan Capital's analyst Daniil Gataulin upgraded CervoMed to Buy from Neutral with a $14 price target, and the overall institutional target price for CervoMed Inc. (CRVO) stock ranges from $10 to $16 with an average price target of around $13.40.

Announcements· Jun 18

CervoMed Inc. ($CRVO) received a notice of allowance from the United States Patent and Trademark Office for a new patent protecting the use of its drug candidate, neflamapimod, in treating dementia with Lewy bodies.
The company expects to raise $10 million in gross proceeds through a registered direct offering of 2.5 million common shares at $4.00 per share, priced at-the-market under Nasdaq rules.
CervoMed secured a new U.S. patent protecting neflamapimod for the treatment of pure dementia with Lewy bodies, extending intellectual property protection into 2042, and has the potential to provide a significant competitive advantage in the market.

Technical Analysis· Jun 16

$CRVO broke above the opening high at 10:45am and stayed in the trade until it broke the 10 ma on the 5 min chart for a gain of over 50%.
$CRVO showed a clean "scalping" SC chart with a leg move that was repeated over and over, resulting in a $6.92 average price.
$CRVO broke through resistance with soaring volume, RSI signaled strong momentum, and the MACD flipped bullish, indicating a strong bull trend.

Generated by AI

Community

Of the messages about CRVO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	33.33%	52.94%	54.22%	20.86%
Newcomers	66.67%	47.06%	45.78%	79.14%

Regulars· Aug 4

The UK Innovation Passport award is a significant milestone for CervoMed's neflamapimod program, accelerating its time to market and expediting patient access to the treatment for Lewy body dementia.
The Innovation Passport award provides CervoMed with early and coordinated guidance from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), the National Health System (NHS), and health technology assessment (HTA) bodies.
The award's benefits include VIP access to the UK's regulatory process, guaranteed insurance coverage, and a de-risked Phase 3 trial roadmap, which could give CervoMed an immediate and accelerated entry point into the European market.

Newcomers· Jul 8

New investors are buying shares of CervoMed Inc. ($CRVO) at its current price of $3.42, with some averaging $5.74.
Many newcomers are concerned about the -4.20% decline in $CRVO and are debating whether it's a temporary dip or a sign of a larger issue, with some considering buying more shares and others cutting losses.
Some investors are focused on the potential upside of $CRVO, with targets ranging from $1.35 to $1.50, and are accumulating shares in anticipation of a momentum phase or a bigger percentage move.

Generated by AI

New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA removal of the prior drug exposure limit provides greater dosing flexibility in future clinical trials CervoMed plans to advance a 100 mg twice-daily regimen expected to achieve higher plasma trough drug concentrations than those associated with clinical activity in prior trials BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. ("CervoMed" or the "Company") (N

2d agoYahoo! Finance Canada

CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 5th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Tuesday, September 29, 2026. Panel DetailsTitle: "Frontiers in Neuroscience"Date: Tuesday, September 29

8d agoYahoo Finance UK

CervoMed at Cantor healthcare conference: phase iii path in focus

18d agoInvesting.com

CervoMed to present nfvPPA trial biomarker data at ISFTD meeting

20d agoInvesting.com

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026

12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting nfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology, currently has no approved treatments in the United States or European Union BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamapimod, an ora

20d agoYahoo Finance

Also Discussed

Investors talking about CRVO also mention

#	Name	Attention
1	YTEN - Yield10 Bioscience, Inc.	——
2	Viveve Medical Inc.VIVE	0%0
3	ASLN - ASLAN Pharmaceuticals Limited	——
4	VBIV - VBI Vaccines Inc.	——
5	GHSI - Guardion Health Sciences, Inc.	——
6	Pulmatrix Inc.PULM	0%0
7	Eltek Ltd.ELTK	0%new
8	Jerash Holdings (US), Inc.JRSH	0%0
9	Tonix Pharmaceuticals Holding CorpTNXP	0.01%+0
10	VIRX - Viracta Therapeutics, Inc.	——

Cervomed Inc

Healthcare
Biotechnology

CervoMed Inc. Common Stock represents CervoMed Inc., a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. The company’s current work centers on advancing CNS-focused therapeutics designed to address degenerative diseases of the brain, with a lead program built around neflamapimod, an investigational orally administered small molecule intended to act on synaptic dysfunction and related neurodegenerative processes. CervoMed’s pipeline targets conditions such as dementia with Lewy bodies and other disorders affecting cognition and neurological function, reflecting its role in the specialized biopharmaceutical sector. As a public company, CervoMed operates within the broader healthcare innovation market, where clinical development, regulatory progress, and therapeutic differentiation are central to its business model. Headquartered in Boston, Massachusetts, CervoMed Inc. serves as a focused small-cap biotechnology participant developing novel approaches for unmet neurological needs.

Website

Location

20 Park Plaza

Boston, MA, 02116

United States

Social

What share of all stock conversation is about CRVO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Sep 29

The stock price of CervoMed Inc. (CRVO) has seen a 42% drop in a short period of time, prompting questions about trading psychology and whether to freeze, fight, or run.
A user suggests that CRVO could see traction with a 20/50 cross to the 3's, indicating a potential technical analysis opportunity.
The stock has seen a significant increase in volume, and some users are optimistic about the company's prospects, with one user stating that "the tipping point is here" and predicting higher prices.

Generated by AI

Sentiment

Of the messages about CRVO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% -50	50% -25	58.33% +7.39	85.63% +10.66
Bearish	50% new	50% +25	41.67% -7.39	14.37% -10.66

Bullish· Jul 8

Morgan Stanley's purchase of CRVO is a bullish sign, and investors who haven't bought yet may still have a chance to do so at a lower price.
The stock's +700% all-time gain has caught the attention of investors, with a target price of $1.40 identified.
CRVO's momentum and the AI boom's need for real-world infrastructure make it a strong investment opportunity, with a target price of $1.35.

Bearish· Jun 22

$CRVO is considered a giant shit fraud stock that will likely be in the red.
A reverse split is expected to occur in less than 3 months, potentially impacting the stock's value.
Investors who got burned by a previous offering may be wary of another potential collapse, citing similar Wall Street games.

Generated by AI

Topics

Of the messages about CRVO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	30.7%
Technical Analysis	—	0%	0%	5.31%
Analysts	—	0%	0%	33.18%
Controversies	—	0%	0%	0.4%
Earnings	—	0%	0%	0.12%
Macro	—	0%	0%	30.29%

Analysts· Mar 13

Chardan Capital upgraded CervoMed (CRVO) to Buy from Neutral with a $14 price target, citing compelling 16-week data from the open label extension phase of the company's Phase 2b study.
Jones Trading adjusted their stance on CervoMed (CRVO) to Buy with a target price of $15, and JonesResearch upgraded CervoMed to Buy from Hold with a $15 price target, arguing that the company's latest data is boosting investor confidence.
Chardan Capital's analyst Daniil Gataulin upgraded CervoMed to Buy from Neutral with a $14 price target, and the overall institutional target price for CervoMed Inc. (CRVO) stock ranges from $10 to $16 with an average price target of around $13.40.

Announcements· Jun 18

CervoMed Inc. ($CRVO) received a notice of allowance from the United States Patent and Trademark Office for a new patent protecting the use of its drug candidate, neflamapimod, in treating dementia with Lewy bodies.
The company expects to raise $10 million in gross proceeds through a registered direct offering of 2.5 million common shares at $4.00 per share, priced at-the-market under Nasdaq rules.
CervoMed secured a new U.S. patent protecting neflamapimod for the treatment of pure dementia with Lewy bodies, extending intellectual property protection into 2042, and has the potential to provide a significant competitive advantage in the market.

Technical Analysis· Jun 16

$CRVO broke above the opening high at 10:45am and stayed in the trade until it broke the 10 ma on the 5 min chart for a gain of over 50%.
$CRVO showed a clean "scalping" SC chart with a leg move that was repeated over and over, resulting in a $6.92 average price.
$CRVO broke through resistance with soaring volume, RSI signaled strong momentum, and the MACD flipped bullish, indicating a strong bull trend.

Generated by AI

Community

Of the messages about CRVO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	33.33%	52.94%	54.22%	20.86%
Newcomers	66.67%	47.06%	45.78%	79.14%

Regulars· Aug 4

The UK Innovation Passport award is a significant milestone for CervoMed's neflamapimod program, accelerating its time to market and expediting patient access to the treatment for Lewy body dementia.
The Innovation Passport award provides CervoMed with early and coordinated guidance from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), the National Health System (NHS), and health technology assessment (HTA) bodies.
The award's benefits include VIP access to the UK's regulatory process, guaranteed insurance coverage, and a de-risked Phase 3 trial roadmap, which could give CervoMed an immediate and accelerated entry point into the European market.

Newcomers· Jul 8

New investors are buying shares of CervoMed Inc. ($CRVO) at its current price of $3.42, with some averaging $5.74.
Many newcomers are concerned about the -4.20% decline in $CRVO and are debating whether it's a temporary dip or a sign of a larger issue, with some considering buying more shares and others cutting losses.
Some investors are focused on the potential upside of $CRVO, with targets ranging from $1.35 to $1.50, and are accumulating shares in anticipation of a momentum phase or a bigger percentage move.

Generated by AI

Cervomed

Social

Sep 29

Bullish· Jul 8

Bearish· Jun 22

Analysts· Mar 13

Announcements· Jun 18

Technical Analysis· Jun 16

Regulars· Aug 4

Newcomers· Jul 8

CervoMed advances higher-dose neflamapimod formulation

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

CervoMed at Cantor healthcare conference: phase iii path in focus

CervoMed to present nfvPPA trial biomarker data at ISFTD meeting

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026

Also Discussed

Cervomed Inc

Company Information

Location

CervoMed advances higher-dose neflamapimod formulation

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

CervoMed at Cantor healthcare conference: phase iii path in focus

CervoMed to present nfvPPA trial biomarker data at ISFTD meeting

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026

Also Discussed

Social

Sep 29

Bullish· Jul 8

Bearish· Jun 22

Analysts· Mar 13

Announcements· Jun 18

Technical Analysis· Jun 16

Regulars· Aug 4

Newcomers· Jul 8